HIGH-GRADE SEROUS OVARIAN CARCINOMA
Clinical trials for HIGH-GRADE SEROUS OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE SEROUS OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for HIGH-GRADE SEROUS OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New mRNA vaccine aims to stop ovarian Cancer's return
Disease control Recruiting nowThis early-stage trial tests a new mRNA cancer vaccine called CryptiVax-1001 in 50 women with advanced ovarian cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells, potentially delaying or preventing the cancer from coming back. The main…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Epitopea Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immune cells trained to fight ovarian cancer in new trial
Disease control Recruiting nowThis early-phase trial tests a new type of immune cell therapy called CIML NK cells in 18 people with recurrent ovarian cancer that no longer responds to standard chemotherapy. The cells are taken from the patient, trained in a lab to better attack cancer, and then infused into t…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New immune drug AZD6750 targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo therapy targets Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. About 172 participants will receive differen…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New pill shows promise against tough cancers – early trial underway
Disease control Recruiting nowThis study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Artios Pharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Accent Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Scientists track immune clues in breast and ovarian tumors
Knowledge-focused Recruiting nowThis study is looking at how the immune system responds to breast and ovarian cancers. Researchers will analyze tumor and blood samples from 160 women before surgery to understand immune cell activity and find markers that might predict survival. The goal is to learn more about h…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Ovarian cancer gene hunt: 300 patients to shape future therapies
Knowledge-focused Recruiting nowThis study aims to collect and analyze genetic information from 300 Taiwanese women with ovarian cancer. Researchers will look at tumor samples and medical records to find gene changes linked to treatment response and survival. The goal is to build a database that helps develop p…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA
Sponsor: National Health Research Institutes, Taiwan • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC